TOVIAZ Drug Patent Profile

When do Toviaz patents expire, and when can generic versions of Toviaz launch?

Toviaz is a drug marketed by Pfizer and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in TOVIAZ is fesoterodine fumarate. There are fifteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the fesoterodine fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Toviaz

A generic version of TOVIAZ was approved as fesoterodine fumarate by ALKEM LABS LTD on December 10^th, 2015.

Summary for TOVIAZ

US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	25
Patent Applications:	220
Drug Prices:	Drug price information for TOVIAZ
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOVIAZ
What excipients (inactive ingredients) are in TOVIAZ?	TOVIAZ excipients list
DailyMed Link:	TOVIAZ at DailyMed

See drug prices for TOVIAZ

See drug sales revenues for TOVIAZ

Recent Clinical Trials for TOVIAZ

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sir Mortimer B. Davis - Jewish General Hospital	Phase 4
University of Alberta	Phase 2
University of British Columbia	Phase 2

See all TOVIAZ clinical trials

Paragraph IV (Patent) Challenges for TOVIAZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TOVIAZ	Extended-release Tablets	fesoterodine fumarate	4 mg and 8 mg	022030	16	2012-10-31

US Patents and Regulatory Information for TOVIAZ

TOVIAZ is protected by three US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No					Y
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes					Y
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No					Y
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008	AB	RX	Yes	No					Y
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes					Y
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008	AB	RX	Yes	Yes					Y

Expired US Patents for TOVIAZ

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-002	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008
Pfizer	TOVIAZ	fesoterodine fumarate	TABLET, EXTENDED RELEASE;ORAL	022030-001	Oct 31, 2008

International Patents for TOVIAZ

See the table below for patents covering TOVIAZ around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	286872
Austria	337293
Austria	395056
Australia	2666701
Australia	778132
Brazil	0015610	composto derivado de 3,3-difenilpropilamina, processo para preparação do mesmo, utilização de intermediários na obtenção do referido composto
Brazil	PI0015610	composto derivado de 3,3-difenilpropilamina, processo para preparação do mesmo, utilização de intermediários na obtenção do referido composto

Supplementary Protection Certificates for TOVIAZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1077912	CA 2007 00046	Denmark		PRODUCT NAME: FESOTERODIN, FUMARAT
1077912	91365	Luxembourg		91365, EXPIRES: 20220420
1077912	07C0050	France		PRODUCT NAME: FESOTERODINE ET SES SELS AVEC DES ACIDES PHYSIOLOGIQUEMENT ACCEPTABLES NOTAMMENT L ACIDE FUMARIQUE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/386/001 DU 20070420; REGISTRATION NO/DATE AT EEC: EU/1/07/386/001 DU 20070420
1077912	SPC037/2007	Ireland		SPC037/2007: 20080507, EXPIRES: 20220419
1077912	SPC/GB07/053	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/053 GRANTED TO SCHWARZ PHARMA AG IN RESPECT OF THE PRODUCT FESOTERODINE AND ITS SALTS WITH PHYSIOLOGICALLY ACCEPTABLE ACIDS, INCLUDING FUMARIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6299 DATED 10 FEBRUARY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 23 APRIL 2022.
1077912	SZ 47/2007	Austria		PRODUCT NAME: FESOTERODINE UND IHRE SALZE MIT PHYSIOLOGISCH ANNEHMBAREN SAEUREN, EINSCHLIESSLICH FUMARSAEURE
1077912	308	Finland

Last updated: July 22, 2026

Toviaz (fesoterodine): market dynamics, pricing, competition, and financial trajectory (2020-2024)

Executive summary: Toviaz (fesoterodine) has shifted from rapid growth to mature, slower-volume dynamics driven by (1) class competition from other overactive bladder (OAB) agents, (2) payer formulary pressure toward lower-cost antimuscarinics and step edits, and (3) episodic supply and generic entry risks around key oral solid-dose segments. Financial trajectory since 2020 has been characterized by modest growth in developed markets and flat-to-soft North America volumes, with branded sales supported mainly by persistence and formulary retention rather than new share gains. The strategic battleground is continued loss of commercially insured share to generics and “preferred” antimuscarinics, while differential outcomes depend on local contracting and patient persistence rather than safety-driven switching.

---

What is Toviaz (fesoterodine) used for and how does OAB competition drive market dynamics?

Toviaz is an oral antimuscarinic indicated for overactive bladder (OAB), including urgency, frequency, and urge urinary incontinence. Market demand is shaped by the OAB treatment funnel: diagnosis rates, symptom severity, line-of-therapy progression, and tolerability (dry mouth and constipation are key drivers of discontinuation and therapy churn).

OAB class structure matters for pricing pressure

• Antimuscarinics: include extended-release formulations (e.g., solifenacin, tolterodine ER, oxybutynin ER, trospium ER, darifenacin).
• β3-agonists: include mirabegron and vibegron, often preferred in patients with antimuscarinic intolerance.
• Combination therapy: antimuscarinic plus β3-agonist where monotherapy fails.

How this translates to Toviaz dynamics

• Toviaz competes on extended-release tolerability profile and dosing convenience within the antimuscarinic bucket.
• As β3-agonists expanded formularies, Toviaz incremental share gains typically slowed, with payer dynamics increasingly determined by cost-per-effective-persistence rather than efficacy alone.

Key commercial levers

• Formulary placement: preferred vs. non-preferred antimuscarinics drives differential use rates.
• Step therapy: requirement to try lower-cost antimuscarinics first reduces first-line Toviaz initiation.
• Persistence: discontinuation due to anticholinergic side effects limits the addressable “continuation” pool.

---

How do generics and formulary contracting affect Toviaz sales trajectories?

Branded antimuscarinic pricing under pressure Toviaz remains exposed to contracting pressure because antimuscarinics are mature classes with multiple off-patent products in many markets. Even when fesoterodine is protected in a jurisdiction for the branded product, the class substitution option is broad.

Generic substitution risk is primarily class-based rather than molecule-based

• Where fesoterodine generics are available, branded volume typically faces sharp erosion unless protected by remaining formulation-specific exclusivity or strong payer contracts.
• Where molecule exclusivity persists, branded sales still face substitution to other antimuscarinics positioned as lower net cost options.

Payer economics OAB is chronic and adherence-driven. Payers negotiate net prices to control total pharmacy spend and shift patients to lower-cost alternatives when clinical differentiation is modest in real-world settings.

---

What competitive landscape determines Toviaz share in 2020–2024?

Direct comparators

• Antimuscarinics (extended release): solifenacin, tolterodine ER, oxybutynin ER, trospium ER, darifenacin.
• β3-agonists: mirabegron, vibegron.
• Combinations: mirabegron plus antimuscarinic in appropriate patients.

Why β3-agonists matter commercially

• β3-agonists are often positioned to reduce anticholinergic burden (dry mouth and constipation).
• This can change payer and provider treatment pathways, especially for patients with adherence challenges.

Implication for Toviaz Toviaz growth is constrained by:

• Share transfer to β3-agonists where payer tiers favor them.
• Patient switching within antimuscarinics based on tolerability and cost.

---

How does Toviaz pricing and net revenue evolve under US and EU reimbursement?

Net pricing is the key variable Branded OAB products typically experience:

• Price pressure from annual contracting cycles and rebate structures.
• Higher sensitivity to formulary tier movement than to list price alone.

US reimbursement dynamics In the US, OAB therapy flows through PBM formulary designs:

• Preferred placement can sustain branded volumes despite generic availability in the class.
• Loss of preferred status triggers immediate prescription re-routing.

EU contracting dynamics In Europe, country-level negotiations and tendering drive:

• Differential persistence by market.
• Variations in share between Northern and Southern European formularies due to differing reimbursement rigidity.

---

What is the financial trajectory of Toviaz: revenue growth, segment role, and volatility?

Trajectory pattern (2020–2024) Toviaz has behaved like a mature branded specialty asset:

• Volume: generally stable in markets with continued payer access, with periodic softness when class alternatives tighten.
• Price: modest decline offset by contract management.
• Mix: improvements possible through persistence and adherence but constrained by side-effect discontinuation.

Volatility sources

• Formulary repricing cycles (net price compression).
• Competitive launches and guideline positioning for β3-agonists.
• Country-level reimbursement changes that can shift OAB prescribing quickly.

Commercial role Toviaz’s role is typically:

• A stable contributor within an OAB franchise portfolio.
• Not a high-growth engine versus newer modalities, but a defensible cash-flow line where contracts remain favorable.

---

When do branded exclusivities end for Toviaz, and how do they affect the generic entry risk?

Exclusivity and patent estates Toviaz faces molecule- and formulation-level patent expiration risk as well as data exclusivity if applicable (jurisdiction-dependent). Generic and authorized generic entry can drive sharp branded erosion.

Generic entry mechanics

• Where a generic enters before broad class competition does, branded volume can still decline due to “cheapest comparable” prescribing habits.
• Where class alternatives are already generic, entry can reduce remaining branded premium faster.

Commercial consequence Even if the branded molecule remains protected, OAB generics in close therapeutic substitutes can limit incremental growth and create a ceiling on share.

---

What patent landscape and litigation risks could change Toviaz market share?

Market share shifts in mature brands usually track patent milestones and settlement outcomes that determine:

• Timing of generic launch.
• Whether authorized generics launch in parallel.
• Whether specific formulation strengths or dosage forms are carved out.

For a molecule like fesoterodine, the relevant commercial risk is less about patent theory and more about practical outcomes:

• Launch timing
• Litigation stay durations
• Scope of design-around (formulation, strength, or release profile)

---

What is the FDA and Orange Book status of Toviaz, and how does it impact financial exposure?

A product’s Orange Book listing informs potential paragraph IV or other generic challenges. For market forecasting, the key financial inputs are:

• Whether any unexpired patents remain listed for the drug product.
• Whether exclusivities block immediate generic substitution.
• Whether generic entries are expected in specific strengths or dosage forms.

Financial linkage

• Remaining exclusivity can support a near-term branded premium.
• Expiration windows determine the “cliff risk” for revenue if a generic is approved and launched rapidly.

---

How strong is Toviaz’s formulation and method-of-use moat versus OAB alternatives?

Formulation matters in mature antimuscarinics Extended-release delivery reduces dosing burden and can improve tolerability through steadier exposure profiles. Formulation differentiation can:

• Support payer acceptance even without major efficacy superiority.
• Reduce substitution to less comparable release profiles.

Moat limitations In a crowded OAB category, clinical differentiation is often modest. The strongest moat tends to be:

• Contracting and persistence
• Local channel access
• Patient-specific tolerability history

---

How does Toviaz compare with mirabegron and vibegron on market positioning and switching risk?

Payer and prescriber switching

• β3-agonists are often favored for patients who discontinue antimuscarinics.
• Switching risk rises when prescribers perceive better tolerability, even if efficacy differences are not decisive.

Implication for Toviaz forecasting Toviaz faces:

• Incremental share capture risk from β3-agonists.
• Higher churn in patients treated in the “tolerability-sensitive” segment.

---

What are the commercial outcomes if a fesoterodine generic enters key markets?

Expected market reaction

• Branded net price compression accelerates.
• Prescription volume typically shifts to lowest-cost equivalent.
• Some residual branded demand persists where contracts protect access or where patients are stable on therapy.

Time-to-impact

• Post-approval launch can shift scripts within the first 1–3 PBM cycles.
• Net revenue erosion usually reflects rebate adjustments and formulary tier changes rather than immediate discontinuation of all branded usage.

---

Key market dynamics by geography: where Toviaz faces the highest erosion pressure?

US

• High sensitivity to formulary tier movements and PBM contracting.
• Faster channel substitution when generics or preferred comparators are available.

EU

• Greater country heterogeneity in reimbursement and tendering.
• Competitive pressure varies by national reimbursement rules and OAB guideline implementation.

Implication The risk profile is highest in:

• Markets with established generic antimuscarinics.
• Systems with strict step edits or strong preferred lists for OAB.

---

What to watch: leading indicators for Toviaz financial trajectory (12–24 month horizon)

1) Formulary placement changes

• Preferred vs. non-preferred movement for antimuscarinics and OAB alternatives.
• Step therapy expansion.

2) PBM rebate and net price renegotiations

• Signs of net price compression beyond expected class dynamics.

3) β3-agonist share gains

• Evidence of sustained uptake reduces the antimuscarinic “add-on” pool.

4) Generic entry announcements

• Molecule-level generic approvals, especially where they coincide with major contracting cycles.

---

Key Takeaways

• Toviaz’s market dynamics are dominated by chronic OAB therapy economics: formulary tiering, step therapy, and persistence rather than one-time prescription spikes.
• Financial trajectory since 2020 is consistent with a mature branded antimuscarinic facing class substitution pressure and incremental erosion risk tied to contracting and category competition.
• The biggest commercial swing factors are (1) payer access changes and (2) competitive shifting toward β3-agonists, with generic entry acting as a catalyst for sharper branded net revenue declines in markets with faster channel substitution.
• Near-term forecasting should focus on PBM formularies, rebate/net price renegotiations, and category share movement into mirabegron/vibegron pathways.

---

FAQs

1. How does Toviaz performance differ between first-line and second-line OAB treatment?
2. What impact do dry mouth and constipation rates have on long-term Toviaz persistence and revenue retention?
3. How do PBM preferred formulary placements typically change OAB branded antimuscarinic sales?
4. What market share shifts are most sensitive to β3-agonist adoption in OAB?
5. How quickly do branded antimuscarinics usually lose prescriptions after generic entry into a mature OAB class?

---

References

No sources provided in the prompt.

DrugChatter Q&A for TOVIAZ

When will toviaz be generic?
Toviaz patent expiry 2027?
Generic substitute for toviaz?
Buy toviaz fesoterodine tablets online?
Toviaz patent expiration 2027?